Using a new radioimmunoassay for the complement-derived anaphylatoxin C3a, both conventional and new low-osmolality contrast agents have been shown to be capable in vitro of activating complement with C3 conversion. The implications of this for some adverse reactions to contrast agents are briefly discussed.
No takes yet. Share an insight, caveat, or question.
Dawson et al. (1983) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: